About Lloyd Sanders

Lloyd Sanders assumed the role of President & Chief Executive Officer of Epic Sciences in March of 2019. Prior to joining Epic, Lloyd was president of the oncology segment at Myriad Genetics responsible for sales, marketing, medical affairs, customer service and laboratory operations for the oncology, urology and dermatology business units. Prior to joining Myriad, he held the position of COO at Dey Pharma, a branded specialty business within the Mylan family of companies. At Genta, a biotechnology company dedicated to the discovery and development of new treatments for cancer, his responsibility increased from VP, Marketing to Chief Commercial Officer and finally Chief Operating Officer in which he oversaw multiple company functions. Mr. Sanders held key senior leadership positions in the commercial organizations of Pharmacia (now Pfizer), Sanofi-Synthelabo and subsequently Sanofi-Aventis. He served at the Vice-President level within the Oncology commercial organizations of Sanofi-Aventis and Sanofi-Synthelabo. In those roles, he had key responsibilities for the commercial success of Eloxatin® (oxaliplatin), Taxotere® (docetaxel), Anzemet® (dolasetron mesylate), and ELITEK® (rasburicase). He led the successful restructuring, integration, deployment, strategic development, and tactical execution of the merged companies’ sales forces. He was responsible for national account GPO contracting strategy and negotiations, and he shared responsibility for oncology sales training and sales operations. At Sanofi-Synthelabo, he led the 110-member team that achieved record sales for an oncology product launch with Eloxatin® (oxaliplatin). From 1987 until 2002, Lloyd held progressively increasing levels of responsibility at Pharmacia, Inc. (now Pfizer).

Specialties: Oncology background with commercial experience in hereditary cancer & molecular diagnostics, colorectal cancer, NSCLC, breast cancer, prostate cancer, melanoma and CLL.